NASDAQ:SGYP

Synergy Pharmaceuticals - SGYP Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: N/A
50-Day Range: $0.01
▼
$0.03
52-Week Range: N/A

Volume: N/A
Average Volume: 6.08 million shs
Market Capitalization: $7.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Synergy Pharmaceuticals (NASDAQ:SGYP) Stock

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Receive SGYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SGYP Stock News Headlines

September 13, 2022 | investing.com

Jiangxi Synergy Pharmaceutical Co Ltd (300636)

May 16, 2022 | seekingalpha.com

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call Transcript

January 18, 2022 | thestreet.com

Here's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying Today

December 2, 2021 | finanznachrichten.de

OKYO Pharma LTD: OKYO Pharma Limited: Directorate Change

October 21, 2020 | markets.businessinsider.com

News for Synergy Pharmaceuticals Inc.

August 20, 2020 | markets.businessinsider.com

Synergy Pharmaceuticals Inc. - Profile

July 23, 2020 | sg.finance.yahoo.com

Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher

May 23, 2020 | www.bloomberg.com

CORRECTING and REPLACING Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update

May 23, 2020 | www.bloomberg.com

Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access Wins

March 18, 2020 | www.marketwatch.com

Identify IBS Treatment Market Regional Growth Drivers Electrifying Development Pace

April 12, 2019 | finance.yahoo.com

FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLD

April 10, 2019 | finance.yahoo.com

DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 9, 2019 | finance.yahoo.com

DEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 9, 2019 | finance.yahoo.com

SGYP & MHLD - Class Action Bronstein, Gewirtz & Grossman, LLC

April 8, 2019 | finance.yahoo.com

SYNERGY INVESTORS APRIL 12th DEADLINE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.; Encourages Investors With Losses In Excess of $100K to Contact the Firm – SGYP

April 5, 2019 | finance.yahoo.com

Class Action Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLD

April 3, 2019 | finance.yahoo.com

Class Action Reminder Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLD

March 29, 2019 | finance.yahoo.com

Bronstein, Gewirtz & Grossman, LLC Class Action Reminder - UXIN, SGYP & MHLD

March 28, 2019 | finance.yahoo.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP

March 28, 2019 | finance.yahoo.com

Bronstein, Gewirtz & Grossman, LLC Class Action Update - UXIN, SGYP & MHLD

March 26, 2019 | finance.yahoo.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

March 21, 2019 | finance.yahoo.com

INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceutical, Inc. (SGYP) and Lead Deadline: April 12, 2019

March 21, 2019 | finance.yahoo.com

INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceuticals, Inc. (SGYP) and Lead Deadline: April 12, 2019

March 20, 2019 | finance.yahoo.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP

March 19, 2019 | finance.yahoo.com

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceutical, Inc. (SGYP) and Lead Deadline: April 12, 2019

See More Headlines

Receive SGYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SGYP Company Calendar

Last Earnings: 11/08/2018
Today: 10/02/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:SGYP
CUSIP: 87163930
CIK: 1347613
Web: www.synergypharma.com
Phone: 212-297-0020
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-224,330,000.00
Net Margins: -332.11%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -118.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.52
Quick Ratio: 0.38

Sales & Book Value

Annual Sales: $16.82 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.02) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 248,040,000
Free Float: N/A
Market Cap: $7.44 million
Optionable: Optionable
Beta: 4.94

Key Executives

Mr. Troy Hamilton Pharm.D. (Age 47)
CEO & Director

Mr. Gary G. Gemignani (Age 54)
Exec. VP & CFO

Gem Gokmen Hopkins
VP of Investor Relations and Corp. Communications

Ms. Pamela Cebulski
Sr. VP of Marketing

Ms. Marianne Jackson
Sr. VP of Sales & Market Access

Key Competitors

View All Competitors

SGYP Stock - Frequently Asked Questions

How were Synergy Pharmaceuticals' earnings last quarter?: Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to analysts' expectations of $15.65 million.
What other stocks do shareholders of Synergy Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and

What is Synergy Pharmaceuticals' stock symbol?: Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."
How much money does Synergy Pharmaceuticals make?: Synergy Pharmaceuticals (NASDAQ:SGYP) has a market capitalization of $0.00 and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.
How can I contact Synergy Pharmaceuticals?: Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The official website for the company is www.synergypharma.com. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at ghopkins@synergypharma.com.

This page (NASDAQ:SGYP) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms